Multiple functions of a glioblastoma fusion oncogene.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 23298839.
- Also identified by DOI 10.1172/JCI67658 and PMC identifier 3561833.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
RNA sequencing facilitates the discovery of novel gene fusions in cancer. In this issue of the JCI, Parker et al. identify an FGFR3-TACC3 fusion oncogene in glioblastoma and demonstrate a novel mechanism of pathogenicity. A miR-99a binding site within the 3'-untranslated region (3'-UTR) of FGFR3 is lost, releasing FGFR3 signaling from miR-99a-dependent inhibition and greatly enhancing tumor progression relative to WT FGFR3. These results provide compelling insight into the pathogenicity of a novel fusion oncogene and suggest new therapeutic approaches for a subset of glioblastomas.
Medical subject headings
- Brain Neoplasms
- Gene Fusion
- Glioblastoma
- MicroRNAs
- Microtubule-Associated Proteins
- Receptor, Fibroblast Growth Factor, Type 3